{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:37:16Z","timestamp":1794062236188,"version":"4.8.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Dysthyroid optic neuropathy (DON) is a rare sight-threatening complication of Graves\u2019 disease. First-line treatment for DON consists of high-dose intravenous methylprednisolone (ivMP), followed by immediate orbital decompression (OD) if the response is poor or absent as recommended by the 2021 European Group on Graves\u2019 orbitopathy guidelines. The safety and efficacy of the proposed therapy have been proven. However, consensus regarding possible therapeutic options for patients with contraindications to ivMP\/OD or resistant form of disease is missing. This paper aims to provide and summarize all available data regarding possible alternative treatment strategies for DON.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive literature search within an electronic database was performed including data published until December 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 52 articles describing use of emerging therapeutic strategies for DON were identified. Collected evidence indicates that biologics, including teprotumumab and tocilizumab, may be considered as an important possible treatment option for DON patients. Rituximab should be avoided in DON due to conflicting data and risk of adverse events. Orbital radiotherapy could be beneficial for patients with restricted ocular motility classified as poor surgical candidates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Only a limited number of studies have been dedicated to the therapy of DON, mostly retrospective with a small sample size. Clear criteria regarding diagnosis and resolution of DON do not exist, which restricts comparison of therapeutic outcomes. Randomized clinical trials and comparison studies with long-term follow-ups are necessary to verify the safety and efficacy of each therapeutic option for DON.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s40618-023-02036-0","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T23:03:16Z","timestamp":1676847796000},"page":"1305-1316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Dysthyroid optic neuropathy: emerging treatment strategies"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7361","authenticated-orcid":false,"given":"M.","family":"Pelewicz-Sowa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9024-9015","authenticated-orcid":false,"given":"P.","family":"Mi\u015bkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,18]]},"reference":[{"key":"2036_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML (2020) Epidemiology, natural history, risk factors, and prevention of graves\u2019 orbitopathy. Front Endocrinol 11:615993","journal-title":"Front Endocrinol"},{"issue":"8","key":"2036_CR2","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1210\/jc.2011-0307","volume":"96","author":"WM Wiersinga","year":"2011","unstructured":"Wiersinga WM (2011) Autoimmunity in graves\u2019 ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 96(8):2386\u20132394","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2036_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40618-021-01663-9","volume":"45","author":"EJ Neag","year":"2022","unstructured":"Neag EJ, Smith TJ (2022) 2021 update on thyroid-associated ophthalmopathy. J Endocrinol Invest 45(2):235\u2013259","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2036_CR4","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","volume":"105","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ (2020) Management of graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab 105(12):3704\u20133720","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2036_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","volume":"121","author":"GB Bartley","year":"1996","unstructured":"Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA et al (1996) Clinical features of Graves\u2019 ophthalmopathy in an incidence cohort. Am J Ophthalmol 121(3):284\u2013290","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2036_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17469899.2017.1276444","volume":"12","author":"AD Blandford","year":"2017","unstructured":"Blandford AD, Zhang D, Chundury RV, Perry JD (2017) Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol 12(2):111\u2013121","journal-title":"Expert Rev Ophthalmol"},{"issue":"3","key":"2036_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40618-020-01361-y","volume":"44","author":"PJ Dolman","year":"2021","unstructured":"Dolman PJ (2021) Dysthyroid optic neuropathy: evaluation and management. J Endocrinol Invest 44(3):421\u2013429","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2036_CR8","first-page":"16360","volume":"133","author":"M Pelewicz-Sowa","year":"2022","unstructured":"Pelewicz-Sowa M, Kajfasz M, Ma\u015bli\u0144ska M, Szczepa\u0144ski M, Pelewicz K, Mi\u015bkiewicz P (2022) IgG4-related disease: sight-threatening orbital disease, spectacular improvement after Rituximab therapy. Pol Arch Intern Med. 133(1):16360","journal-title":"Pol Arch Intern Med."},{"issue":"4","key":"2036_CR9","first-page":"16193","volume":"132","author":"P Chrostowska","year":"2022","unstructured":"Chrostowska P, Drozd-Soko\u0142owska J, Mi\u015bkiewicz P (2022) Erdheim-Chester disease with orbital involvement and progressive impairment of vision. Polish Arch Intern Med. 132(4):16193","journal-title":"Polish Arch Intern Med."},{"issue":"4","key":"2036_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40618-019-01141-3","volume":"43","author":"M Marin\u00f2","year":"2020","unstructured":"Marin\u00f2 M, Ionni I, Lanzolla G, Sframeli A, Latrofa F, Rocchi R et al (2020) Orbital diseases mimicking Graves\u2019 orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest 43(4):401\u2013411","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2036_CR11","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C et al (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185(4):G43-67","journal-title":"Eur J Endocrinol"},{"key":"2036_CR12","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM et al (2022) Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. https:\/\/doi.org\/10.1530\/ETJ-22-0189","journal-title":"Eur Thyroid J."},{"issue":"3","key":"2036_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","volume":"63","author":"IMMJ Wakelkamp","year":"2005","unstructured":"Wakelkamp IMMJ, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM (2005) Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves\u2019 ophthalmopathy? A randomized controlled trial. Clin Endocrinol 63(3):323\u2013328","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2036_CR14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2013.0445","volume":"24","author":"N Curr\u00f2","year":"2014","unstructured":"Curr\u00f2 N, Covelli D, Vannucchi G, Campi I, Pirola G, Simonetta S et al (2014) Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid 24(5):897\u2013905","journal-title":"Thyroid"},{"key":"2036_CR15","doi-asserted-by":"publisher","first-page":"9323450","DOI":"10.1155\/2020\/9323450","volume":"2020","author":"J Xu","year":"2020","unstructured":"Xu J, Ye H, Chen G, Chen J, Chen R, Yang H (2020) The therapeutic effect of combination of orbital decompression surgery and methylprednisolone pulse therapy on patients with bilateral dysthyroid optic neuropathy. J Ophthalmol 2020:9323450","journal-title":"J Ophthalmol"},{"issue":"11","key":"2036_CR16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.18240\/ijo.2019.11.12","volume":"12","author":"Y Wen","year":"2019","unstructured":"Wen Y, Yan J-H (2019) The effect of intravenous high-dose glucocorticoids and orbital decompression surgery on sight-threatening thyroid-associated ophthalmopathy. Int J Ophthalmol 12(11):1737\u20131745","journal-title":"Int J Ophthalmol"},{"issue":"11","key":"2036_CR17","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1007\/s00417-022-05732-4","volume":"260","author":"S Rezar-Dreindl","year":"2022","unstructured":"Rezar-Dreindl S, Papp A, Baumann A, Neumayer T, Eibenberger K, Stifter E et al (2022) Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and\/or orbital decompression surgery. Graefe\u2019s Arch Clin Exp Ophthalmol. 260(11):3683\u20133691","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol."},{"issue":"9","key":"2036_CR18","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41433-020-0897-x","volume":"34","author":"A Garip Kuebler","year":"2020","unstructured":"Garip Kuebler A, Wiecha C, Reznicek L, Klingenstein A, Halfter K, Priglinger S et al (2020) Evaluation of medical and surgical decompression in patients with dysthyroid optic neuropathy. Eye 34(9):1702\u20131709","journal-title":"Eye"},{"issue":"1","key":"2036_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/cen.13880","volume":"90","author":"B Tramunt","year":"2019","unstructured":"Tramunt B, Imbert P, Grunenwald S, Boutault F, Caron P (2019) Sight-threatening Graves\u2019 orbitopathy: Twenty years\u2019 experience of a multidisciplinary thyroid-eye outpatient clinic. Clin Endocrinol 90(1):208\u2013213","journal-title":"Clin Endocrinol"},{"issue":"2","key":"2036_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3341\/kjo.2012.26.2.73","volume":"26","author":"C Jeon","year":"2012","unstructured":"Jeon C, Shin JH, Woo KI, Kim Y-D (2012) Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy. Korean J Ophthalmol 26(2):73\u201379","journal-title":"Korean J Ophthalmol"},{"issue":"7","key":"2036_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0161-6420(89)32784-9","volume":"96","author":"JR Guy","year":"1989","unstructured":"Guy JR, Fagien S, Donovan JP, Rubin ML (1989) Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology 96(7):1043\u20131048","journal-title":"Ophthalmology"},{"issue":"2","key":"2036_CR22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5603\/EP.a2016.0018","volume":"67","author":"P Mi\u015bkiewicz","year":"2016","unstructured":"Mi\u015bkiewicz P, Rutkowska B, Jab\u0142o\u0144ska A, Krzeski A, Trautsolt-Jeziorska K, K\u0119cik D et al (2016) Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy. Endokrynol Pol 67(2):166\u2013173","journal-title":"Endokrynol Pol"},{"issue":"2","key":"2036_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/01676830.2014.949784","volume":"34","author":"SX Zhang-Nunes","year":"2015","unstructured":"Zhang-Nunes SX, Dang S, Garneau HC, Hwang C, Isaacs D, Chang S-H et al (2015) Characterization and outcomes of repeat orbital decompression for thyroid-associated orbitopathy. Orbit 34(2):57\u201365","journal-title":"Orbit"},{"issue":"4","key":"2036_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1076\/orbi.20.4.275.2612","volume":"20","author":"M Ph Mourits","year":"2001","unstructured":"Ph Mourits M, Kalmann R, Sasim IV (2001) Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy. Orbit 20(4):275\u2013280","journal-title":"Orbit"},{"issue":"5","key":"2036_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/IOP.0000000000000356","volume":"31","author":"CY Kauh","year":"2015","unstructured":"Kauh CY, Gupta S, Douglas RS, Elner VM, Nelson CC, Niziol LM et al (2015) Compressive optic neuropathy and repeat orbital decompression: a case series. Ophthal Plast Reconstr Surg 31(5):385\u2013390","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"1","key":"2036_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/00002341-199403000-00007","volume":"10","author":"R Wenz","year":"1994","unstructured":"Wenz R, Levine MR, Putterman A, Bersani T, Feldman K (1994) Extraocular muscle enlargement after orbital decompression for Graves\u2019 ophthalmopathy. Ophthal Plast Reconstr Surg 10(1):34\u201341","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"5","key":"2036_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5603\/EP.2014.0056","volume":"65","author":"P Mi\u015bkiewicz","year":"2014","unstructured":"Mi\u015bkiewicz P, Kryczka A, Ambroziak U, Rutkowska B, G\u0142\u00f3wczy\u0144ska R, Opolski G et al (2014) Is high dose intravenous methylprednisolone pulse therapy in patients with Graves\u2019 orbitopathy safe? Endokrynol Pol 65(5):402\u2013413","journal-title":"Endokrynol Pol"},{"issue":"2","key":"2036_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320\u2013332","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2036_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1530\/EJE-11-0779","volume":"166","author":"C Marcocci","year":"2012","unstructured":"Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen U, Orgiazzi J et al (2012) Fatal and non-fatal adverse events of glucocorticoid therapy for Graves\u2019 orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol 166(2):247\u2013253","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2036_CR30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0002-9394(14)73194-0","volume":"116","author":"JA Garrity","year":"1993","unstructured":"Garrity JA, Fatourechi V, Bergstralh EJ, Bartley GB, Beatty CW, DeSanto LW et al (1993) Results of transantral orbital decompression in 428 patients with severe Graves\u2019 ophthalmopathy. Am J Ophthalmol 116(5):533\u2013547","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2036_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2265.2007.02845.x","volume":"67","author":"M Jernfors","year":"2007","unstructured":"Jernfors M, V\u00e4lim\u00e4ki MJ, Set\u00e4l\u00e4 K, Malmberg H, Laitinen K, Pitk\u00e4ranta A (2007) Efficacy and safety of orbital decompression in treatment of thyroid-associated ophthalmopathy: long-term follow-up of 78 patients. Clin Endocrinol (Oxf) 67(1):101\u2013107","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2036_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/105072504774193276","volume":"14","author":"M Marin\u00f3","year":"2004","unstructured":"Marin\u00f3 M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C (2004) Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves\u2019 ophthalmopathy. Thyroid 14(5):403\u2013406","journal-title":"Thyroid"},{"issue":"4","key":"2036_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/thy.2006.0267","volume":"17","author":"R Le Moli","year":"2007","unstructured":"Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM (2007) Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves\u2019 ophthalmopathy. Thyroid 17(4):357\u2013362","journal-title":"Thyroid"},{"issue":"3","key":"2036_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/eye.2017.260","volume":"32","author":"JM Jefferis","year":"2018","unstructured":"Jefferis JM, Jones RK, Currie ZI, Tan JH, Salvi SM (2018) Orbital decompression for thyroid eye disease: methods, outcomes, and complications. Eye 32(3):626\u2013636","journal-title":"Eye"},{"issue":"6","key":"2036_CR35","doi-asserted-by":"publisher","first-page":"E1059","DOI":"10.1093\/neuros\/nyz268","volume":"85","author":"G Zah-Bi","year":"2019","unstructured":"Zah-Bi G, Abeillon-du Payrat J, Vie AL, Bournaud-Salinas C, Jouanneau E, Berhouma M (2019) Minimal-access endoscopic endonasal management of dysthyroid optic neuropathy: the dysthone study. Neurosurgery 85(6):E1059\u2013E1067","journal-title":"Neurosurgery"},{"issue":"10","key":"2036_CR36","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3390\/jpm12101714","volume":"12","author":"KB Po\u015blednik","year":"2022","unstructured":"Po\u015blednik KB, Czerwaty K, Ludwig N, Moli\u0144ska-Glura M, Jab\u0142o\u0144ska-Pawlak A, Mi\u015bkiewicz P et al (2022) Treatment results of endoscopic transnasal orbital decompression for graves\u2019 orbitopathy-a single-center retrospective analysis in 28 orbits of 16 patients. J Pers Med. 12(10):1714","journal-title":"J Pers Med."},{"issue":"1","key":"2036_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40662-021-00238-2","volume":"8","author":"Y Tu","year":"2021","unstructured":"Tu Y, Xu M, Kim AD, Wang MTM, Pan Z, Wu W (2021) Modified endoscopic transnasal orbital apex decompression in dysthyroid optic neuropathy. Eye Vis 8(1):19","journal-title":"Eye Vis"},{"issue":"10","key":"2036_CR38","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41433-019-0464-5","volume":"33","author":"S Singh","year":"2019","unstructured":"Singh S, Curragh DS, Selva D (2019) Augmented endoscopic orbital apex decompression in dysthyroid optic neuropathy. Eye 33(10):1613\u20131618","journal-title":"Eye"},{"issue":"2","key":"2036_CR39","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3109\/02713683.2015.1008640","volume":"41","author":"Z Lv","year":"2016","unstructured":"Lv Z, Selva D, Yan W, Daniel P, Tu Y, Wu W (2016) Endoscopical orbital fat decompression with medial orbital wall decompression for dysthyroid optic neuropathy. Curr Eye Res 41(2):150\u2013158","journal-title":"Curr Eye Res"},{"issue":"3","key":"2036_CR40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/00005537-200303000-00021","volume":"113","author":"SD Schaefer","year":"2003","unstructured":"Schaefer SD, Soliemanzadeh P, Della Rocca DA, Yoo G-P, Maher EA, Milite JP et al (2003) Endoscopic and transconjunctival orbital decompression for thyroid-related orbital apex compression. Laryngoscope 113(3):508\u2013513","journal-title":"Laryngoscope"},{"issue":"9","key":"2036_CR41","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/lary.25320","volume":"125","author":"TT Kingdom","year":"2015","unstructured":"Kingdom TT, Davies BW, Durairaj VD (2015) Orbital decompression for the management of thyroid eye disease: an analysis of outcomes and complications. Laryngoscope 125(9):2034\u20132040","journal-title":"Laryngoscope"},{"issue":"6","key":"2036_CR42","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.anl.2019.03.010","volume":"46","author":"K Nishimura","year":"2019","unstructured":"Nishimura K, Takahashi Y, Katahira N, Uchida Y, Ueda H, Ogawa T (2019) Visual changes after transnasal endoscopic versus transcaruncular medial orbital wall decompression for dysthyroid optic neuropathy. Auris Nasus Larynx 46(6):876\u2013881","journal-title":"Auris Nasus Larynx"},{"issue":"8","key":"2036_CR43","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0161-6420(00)00241-4","volume":"107","author":"N Shorr","year":"2000","unstructured":"Shorr N, Baylis HI, Goldberg RA, Perry JD (2000) Transcaruncular approach to the medial orbit and orbital apex. Ophthalmology 107(8):1459\u20131463","journal-title":"Ophthalmology"},{"key":"2036_CR44","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ajo.2006.08.020","volume":"142","author":"JD Perry","year":"2006","unstructured":"Perry JD (2006) Transcaruncular orbital decompression: an alternate procedure for graves ophthalmopathy with compressive optic neuropathy. Am J Ophthalmol 142:889 (Author reply 889-90)","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2036_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/02713683.2015.1008641","volume":"41","author":"S Korkmaz","year":"2016","unstructured":"Korkmaz S, Konuk O (2016) Surgical treatment of dysthyroid optic neuropathy: long-term visual outcomes with comparison of 2-wall versus 3-wall orbital decompression. Curr Eye Res 41(2):159\u2013164","journal-title":"Curr Eye Res"},{"issue":"8","key":"2036_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024513","volume":"100","author":"S-N Cheng","year":"2021","unstructured":"Cheng S-N, Yu Y-Q, You Y-Y, Chen J, Pi X-H, Wang X-H et al (2021) Comparison of 2-wall versus 3-wall orbital decompression against dysthyroid optic neuropathy in visual function: a retrospective study in a Chinese population. Medicine 100(8):e24513","journal-title":"Medicine"},{"issue":"3","key":"2036_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2022.103451","volume":"43","author":"I Dallan","year":"2022","unstructured":"Dallan I, Cristofani-Mencacci L, Fiacchini G, Benettini G, Picariello M, Lanzolla G et al (2022) Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols. Am J Otolaryngol 43(3):103451","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"2036_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/IOP.0b013e3181df6a87","volume":"27","author":"CH Choe","year":"2011","unstructured":"Choe CH, Cho RI, Elner VM (2011) Comparison of lateral and medial orbital decompression for the treatment of compressive optic neuropathy in thyroid eye disease. Ophthal Plast Reconstr Surg 27(1):4\u201311","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"1","key":"2036_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12886-020-1314-8","volume":"20","author":"M Tagami","year":"2020","unstructured":"Tagami M, Honda S, Azumi A (2020) Preoperative clinical factors and visual outcomes following orbital decompression with dysthyroid optic neuropathy. BMC Ophthalmol 20(1):30","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"2036_CR50","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/jcm11082068","volume":"11","author":"M Pelewicz","year":"2022","unstructured":"Pelewicz M, Rymuza J, Pelewicz K, Mi\u015bkiewicz P (2022) Dysthyroid optic neuropathy: treatment with additional intravenous methylprednisolone pulses after the basic schedule is associated with stabilization or further improvement of clinical outcome. J Clin Med 11(8):2068","journal-title":"J Clin Med"},{"key":"2036_CR51","doi-asserted-by":"crossref","unstructured":"Pelewicz M, Rymuza J, Pelewicz K, Mi\u015bkiewicz P (2021) Impact of additional intravenous methylprednisolone pulse therapy on the quality of life in patients with dysthyroid optic neuropathy. J Med Sci [Internet]. 28;90(2 SE-Original Papers):e519. Available from: https:\/\/jms.ump.edu.pl\/index.php\/JMS\/article\/view\/519. Accessed 28 Nov 2022","DOI":"10.20883\/medical.e519"},{"issue":"6","key":"2036_CR52","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A et al (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J Immunol 181(6):4397\u20134405","journal-title":"J Immunol"},{"issue":"18","key":"2036_CR53","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376(18):1748\u20131761","journal-title":"N Engl J Med"},{"issue":"8","key":"2036_CR54","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","volume":"181","author":"RS Douglas","year":"2008","unstructured":"Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D et al (2008) B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 181(8):5768\u20135774","journal-title":"J Immunol"},{"issue":"4","key":"2036_CR55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382(4):341\u2013352","journal-title":"N Engl J Med"},{"issue":"3","key":"2036_CR56","doi-asserted-by":"publisher","first-page":"NP46","DOI":"10.1177\/1120672121991042","volume":"32","author":"CJ Hwang","year":"2022","unstructured":"Hwang CJ, Nichols EE, Chon BH, Perry JD (2022) Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab. Eur J Ophthalmol 32(3):NP46\u2013NP49","journal-title":"Eur J Ophthalmol"},{"key":"2036_CR57","doi-asserted-by":"publisher","first-page":"101484","DOI":"10.1016\/j.ajoc.2022.101484","volume":"26","author":"OT Cheng","year":"2022","unstructured":"Cheng OT, Schlachter DM (2022) Teprotumumab in advanced reactivated thyroid eye disease. Am J Ophthalmol Case Rep. 26:101484","journal-title":"Am J Ophthalmol Case Rep."},{"issue":"3S","key":"2036_CR58","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1097\/IOP.0000000000001831","volume":"37","author":"CM Sears","year":"2021","unstructured":"Sears CM, Azad AD, Dosiou C, Kossler AL (2021) Teprotumumab for dysthyroid optic neuropathy: early response to therapy. Ophthal Plast Reconstr Surg 37(3S):S157\u2013S160","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"2","key":"2036_CR59","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1097\/WNO.0000000000001298","volume":"42","author":"MJ Lopez","year":"2022","unstructured":"Lopez MJ, Herring JL, Thomas C, Bertram BA, Thomas DA (2022) Visual recovery of dysthyroid optic neuropathy with teprotumumab. J Neuro-ophthalmol 42(2):e491\u2013e493","journal-title":"J Neuro-ophthalmol"},{"key":"2036_CR60","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jamaophthalmol.2020.5296","volume":"139","author":"DH Slentz","year":"2021","unstructured":"Slentz DH, Smith TJ, Kim DS, Joseph SS (2021) Teprotumumab for optic neuropathy in thyroid eye disease. JAMA Ophthalmol. 139:244\u2013247","journal-title":"JAMA Ophthalmol."},{"key":"2036_CR61","doi-asserted-by":"publisher","first-page":"101075","DOI":"10.1016\/j.ajoc.2021.101075","volume":"22","author":"CA Chiou","year":"2021","unstructured":"Chiou CA, Reshef ER, Freitag SK (2021) Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: a report of two cases. Am J Ophthalmol Case Rep. 22:101075","journal-title":"Am J Ophthalmol Case Rep."},{"issue":"6","key":"2036_CR62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/IOP.0000000000001959","volume":"37","author":"SB Diniz","year":"2021","unstructured":"Diniz SB, Cohen LM, Roelofs KA, Rootman DB (2021) Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthal Plast Reconstr Surg 37(6):583\u2013591","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2036_CR63","doi-asserted-by":"publisher","first-page":"101111","DOI":"10.1016\/j.ajoc.2021.101111","volume":"23","author":"CM Sears","year":"2021","unstructured":"Sears CM, Wang Y, Bailey LA, Turbin R, Subramanian PS, Douglas R et al (2021) Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study. Am J Ophthalmol Case Rep. 23:101111","journal-title":"Am J Ophthalmol Case Rep."},{"issue":"3","key":"2036_CR64","first-page":"1194","volume":"85","author":"Y Hiromatsu","year":"2000","unstructured":"Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y (2000) Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 85(3):1194\u20131199","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2036_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/07435800.2011.635622","volume":"37","author":"M Slowik","year":"2012","unstructured":"Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, Kapelko-Slowik K, Dybko J, Wolowiec D et al (2012) CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves\u2019 orbitopathy and correlate with disease activity. Endocr Res 37(2):89\u201395","journal-title":"Endocr Res"},{"issue":"9","key":"2036_CR66","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1089\/thy.2007.0407","volume":"18","author":"GM Lehmann","year":"2008","unstructured":"Lehmann GM, Feldon SE, Smith TJ, Phipps RP (2008) Immune mechanisms in thyroid eye disease. Thyroid 18(9):959\u2013965","journal-title":"Thyroid"},{"key":"2036_CR67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM et al (2018) Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 195:181\u2013190","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2036_CR68","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/jcm10040706","volume":"10","author":"JV P\u00e9rez-Moreiras","year":"2021","unstructured":"P\u00e9rez-Moreiras JV, Varela-Agra M, Prada-S\u00e1nchez MC, Prada-Ramallal G (2021) Steroid-resistant graves\u2019 orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience. J Clin Med 10(4):706","journal-title":"J Clin Med"},{"issue":"2\u20133","key":"2036_CR69","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ando.2020.01.003","volume":"81","author":"J Ceballos-Mac\u00edas Jos\u00e9","year":"2020","unstructured":"Ceballos-Mac\u00edas Jos\u00e9 J, Rivera-Moscoso R, Flores-Real Jorge A, Vargas-S\u00e1nchez J, Ortega-Guti\u00e9rrez G, Madriz-Prado R et al (2020) Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population. Ann Endocrinol 81(2\u20133):78\u201382","journal-title":"Ann Endocrinol"},{"issue":"9","key":"2036_CR70","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.3390\/jcm9092816","volume":"9","author":"L S\u00e1nchez-Bilbao","year":"2020","unstructured":"S\u00e1nchez-Bilbao L, Mart\u00ednez-L\u00f3pez D, Revenga M, L\u00f3pez-V\u00e1zquez \u00c1, Valls-Pascual E, Atienza-Mateo B et al (2020) Anti-IL-6 receptor tocilizumab in refractory graves\u2019 orbitopathy: national multicenter observational study of 48 patients. J Clin Med 9(9):2816","journal-title":"J Clin Med"},{"issue":"6","key":"2036_CR71","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/01676830.2018.1435694","volume":"37","author":"I Pascual-Camps","year":"2018","unstructured":"Pascual-Camps I, Molina-Pallete R, Bort-Mart\u00ed MA, Todol\u00ed J, Espa\u00f1a-Gregori E (2018) Tocilizumab as first treatment option in optic neuropathy secondary to Graves\u2019 orbitopathy. Orbit 37(6):450\u2013453","journal-title":"Orbit"},{"issue":"1","key":"2036_CR72","first-page":"64","volume":"64","author":"A Mehmet","year":"2021","unstructured":"Mehmet A, Panagiotopoulou EK, Konstantinidis A, Papagoras C, Skendros P, Dardabounis D et al (2021) \u0391 case of severe thyroid eye disease treated with tocilizumab. Acta Medica Hradec Kral. 64(1):64\u201369","journal-title":"Acta Medica Hradec Kral."},{"issue":"3","key":"2036_CR73","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1097\/IOP.0000000000000730","volume":"33","author":"A Sy","year":"2017","unstructured":"Sy A, Eliasieh K, Silkiss RZ (2017) Clinical response to tocilizumab in severe thyroid eye disease. Ophthal Plast Reconstr Surg 33(3):e55\u2013e57","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2036_CR74","first-page":"448","volume":"38","author":"L G\u00f3mez Rodr\u00edguez","year":"2014","unstructured":"G\u00f3mez Rodr\u00edguez L, C\u00e1rdenas Aranzana MJ, Avil\u00e9s MC (2014) Effectiveness and safety of tocilizumab in corticoid refractory Graves\u2019 orbitopathy. Farm Hosp 38:448\u2013450","journal-title":"Farm Hosp"},{"key":"2036_CR75","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/09273948.2018.1545914","volume":"28","author":"T Maldiney","year":"2020","unstructured":"Maldiney T, Deschasse C, Bielefeld P (2020) Tocilizumab for the management of corticosteroid-resistant mild to severe Graves\u2019 ophthalmopathy, a report of three cases. Ocul Immunol Inflamm 28:281\u2013284","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"2036_CR76","doi-asserted-by":"publisher","first-page":"SAT-500","DOI":"10.1210\/jendso\/bvaa046.1316","volume":"4","author":"D Kaplan","year":"2020","unstructured":"Kaplan D, Erickson B, Kossler A, Chen J, Dosiou C (2020) SAT-500 response to tocilizumab retreatment in refractory thyroid eye disease. J Endocr Soc. 4(1):SAT-500","journal-title":"J Endocr Soc."},{"issue":"11","key":"2036_CR77","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1210\/jc.2013-1804","volume":"98","author":"M Salvi","year":"2013","unstructured":"Salvi M, Vannucchi G, Beck-Peccoz P (2013) Potential utility of rituximab for Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98(11):4291\u20134299","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2036_CR78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C et al (2016) The 2016 European thyroid association\/European group on Graves\u2019 orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J 5(1):9\u201326","journal-title":"Eur Thyroid J"},{"issue":"2","key":"2036_CR79","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS (2015) Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab 100(2):432\u2013441","journal-title":"J Clin Endocrinol Metab"},{"key":"2036_CR80","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1365-2265.2009.03762.x","volume":"72","author":"GE Krassas","year":"2010","unstructured":"Krassas GE, Stafilidou A, Boboridis KG (2010) Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clin Endocrinol 72:853\u2013855","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2036_CR81","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/thy.2020.0269","volume":"31","author":"G Vannucchi","year":"2021","unstructured":"Vannucchi G, Campi I, Covelli D, Curr\u00f2 N, Lazzaroni E, Palomba A et al (2021) efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid 31(5):821\u2013828","journal-title":"Thyroid"},{"issue":"1","key":"2036_CR82","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cen.13970","volume":"91","author":"EA Insull","year":"2019","unstructured":"Insull EA, Sipkova Z, David J, Turner HE, Norris JH (2019) Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment. Clin Endocrinol 91(1):179\u2013186","journal-title":"Clin Endocrinol"},{"issue":"2","key":"2036_CR83","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Campi I, Covelli D, Dazzi D et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100(2):422\u2013431","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2036_CR84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M Salvi","year":"2007","unstructured":"Salvi M, Vannucchi G, Campi I, Curr\u00f2 N, Dazzi D, Simonetta S et al (2007) Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156(1):33\u201340","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2036_CR85","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clim.2008.12.005","volume":"131","author":"M Salvi","year":"2009","unstructured":"Salvi M, Vannucchi G, Campi I, Curr\u00f2 N, Simonetta S, Covelli D et al (2009) Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 131(2):360\u2013365","journal-title":"Clin Immunol"},{"issue":"1","key":"2036_CR86","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1097\/IOP.0b013e31828956a8","volume":"30","author":"AJ Gess","year":"2014","unstructured":"Gess AJ, Silkiss RZ (2014) Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 30(1):e11\u2013e13","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"3","key":"2036_CR87","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cen.12141","volume":"79","author":"AL Mitchell","year":"2013","unstructured":"Mitchell AL, Gan EH, Morris M, Johnson K, Neoh C, Dickinson AJ et al (2013) The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy. Clin Endocrinol 79(3):437\u2013442","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2036_CR88","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","volume":"117","author":"D Khanna","year":"2010","unstructured":"Khanna D, Chong KKL, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC et al (2010) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 117(1):133-139.e2","journal-title":"Ophthalmology"},{"key":"2036_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.583565","volume":"11","author":"B Zhang","year":"2020","unstructured":"Zhang B, Li Y, Xu W, Peng B, Yuan G (2020) Use of rituximab after orbital decompression surgery in two Grave\u2019s ophthalmopathy patients progressing to optic neuropathy. Front Endocrinol 11:583565","journal-title":"Front Endocrinol"},{"issue":"2\u20133","key":"2036_CR90","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2\u20133):85\u2013118","journal-title":"Immunopharmacology"},{"issue":"2","key":"2036_CR91","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1124\/jpet.106.117051","volume":"321","author":"N Roos","year":"2007","unstructured":"Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F (2007) In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 321(2):583\u2013589","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2036_CR92","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/01.TP.0000101822.50960.AB","volume":"77","author":"A Azzola","year":"2004","unstructured":"Azzola A, Havryk A, Chhajed P, Hostettler K, Black J, Johnson P et al (2004) Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 77(2):275\u2013280","journal-title":"Transplantation"},{"issue":"2","key":"2036_CR93","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/cen.13170","volume":"86","author":"X Ye","year":"2017","unstructured":"Ye X, Bo X, Hu X, Cui H, Lu B, Shao J et al (2017) Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy. Clin Endocrinol 86(2):247\u2013255","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2036_CR94","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, K\u00f6nig J, Pitz S, Ponto K, Diana T et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6(4):287\u2013298","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2036_CR95","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40618-016-0441-9","volume":"39","author":"M Riedl","year":"2016","unstructured":"Riedl M, Kuhn A, Kr\u00e4mer I, Kolbe E, Kahaly GJ (2016) Prospective, systematically recorded mycophenolate safety data in Graves\u2019 orbitopathy. J Endocrinol Invest 39(6):687\u2013694","journal-title":"J Endocrinol Invest"},{"key":"2036_CR96","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2147\/OPTH.S305717","volume":"15","author":"N Quah Qin Xian","year":"2021","unstructured":"Quah Qin Xian N, Alnahrawy A, Akshikar R, Lee V (2021) Real-world efficacy and safety of mycophenolate mofetil in active moderate-to-sight-threatening thyroid eye disease. Clin Ophthalmol 15:1921\u20131932","journal-title":"Clin Ophthalmol"},{"issue":"32","key":"2036_CR97","doi-asserted-by":"publisher","first-page":"14205","DOI":"10.1073\/pnas.1002213107","volume":"107","author":"S Grudzenski","year":"2010","unstructured":"Grudzenski S, Raths A, Conrad S, R\u00fcbe CE, L\u00f6brich M (2010) Inducible response required for repair of low-dose radiation damage in human fibroblasts. Proc Natl Acad Sci U S A 107(32):14205\u201314210","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2036_CR98","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/IOP.0000000000001003","volume":"34","author":"KG Gold","year":"2018","unstructured":"Gold KG, Scofield S, Isaacson SR, Stewart MW, Kazim M (2018) Orbital radiotherapy combined with corticosteroid treatment for thyroid eye disease-compressive optic neuropathy. Ophthal Plast Reconstr Surg 34(2):172\u2013177","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"9","key":"2036_CR99","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S0161-6420(91)32114-6","volume":"98","author":"M Kazim","year":"1991","unstructured":"Kazim M, Trokel S, Moore S (1991) Treatment of acute Graves orbitopathy. Ophthalmology 98(9):1443\u20131448","journal-title":"Ophthalmology"},{"issue":"6","key":"2036_CR100","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/01676830.2011.615455","volume":"30","author":"JFT Li Yim","year":"2011","unstructured":"Li Yim JFT, Sandinha T, Kerr JM, Ritchie D, Kemp EG (2011) Low dose orbital radiotherapy for thyroid eye disease. Orbit 30(6):269\u2013274","journal-title":"Orbit"},{"issue":"4","key":"2036_CR101","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0360-3016(98)00405-2","volume":"43","author":"V Beckendorf","year":"1999","unstructured":"Beckendorf V, Maalouf T, George JL, Bey P, Leclere J, Luporsi E (1999) Place of radiotherapy in the treatment of Graves\u2019 orbitopathy. Int J Radiat Oncol Biol Phys 43(4):805\u2013815","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2036_CR102","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0002-9394(75)90083-5","volume":"79","author":"JG Ravin","year":"1975","unstructured":"Ravin JG, Sisson JC, Knapp WT (1975) Orbital radiation for the ocular changes of Gravess\u2019 disease. Am J Ophthalmol 79(2):285\u2013288","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2036_CR103","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1148\/122.3.797","volume":"122","author":"EE Covington","year":"1977","unstructured":"Covington EE, Lobes L, Sudarsanam A (1977) Radiation therapy for exophthalmos: report of seven cases. Radiology 122(3):797\u2013799","journal-title":"Radiology"},{"issue":"2","key":"2036_CR104","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0002-9394(14)77786-4","volume":"96","author":"GJ Panzo","year":"1983","unstructured":"Panzo GJ, Tomsak RL (1983) A retrospective review of 26 cases of dysthyroid optic neuropathy. Am J Ophthalmol 96(2):190\u2013194","journal-title":"Am J Ophthalmol"},{"issue":"Pt 5","key":"2036_CR105","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/eye.1997.183","volume":"11","author":"KG Claridge","year":"1997","unstructured":"Claridge KG, Ghabrial R, Davis G, Tomlinson M, Goodman S, Harrad RA et al (1997) Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease. Eye 11(Pt 5):717\u2013722","journal-title":"Eye"},{"issue":"12","key":"2036_CR106","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/0360-3016(87)90346-4","volume":"13","author":"D Palmer","year":"1987","unstructured":"Palmer D, Greenberg P, Cornell P, Parker RG (1987) Radiation therapy for Graves\u2019 ophthalmopathy: a retrospective analysis. Int J Radiat Oncol Biol Phys 13(12):1815\u20131820","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2036_CR107","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12902-018-0235-5","volume":"18","author":"S Zhang","year":"2018","unstructured":"Zhang S, Wang Y, Zhong S, Liu X, Huang Y, Fang S et al (2018) Orbital radiotherapy plus three-wall orbital decompression in a patient with rare ocular manifestations of thyroid eye disease: case report. BMC Endocr Disord 18(1):7","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"2036_CR108","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/01676830.2014.904378","volume":"33","author":"D Hersh","year":"2014","unstructured":"Hersh D, Kinnar M (2014) Acute dysthyroid optic neuropathy exacerbated by orbital radiotherapy. Orbit 33(5):385\u2013387","journal-title":"Orbit"},{"issue":"1","key":"2036_CR109","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0360-3016(99)00528-3","volume":"47","author":"S Rush","year":"2000","unstructured":"Rush S, Winterkorn JM, Zak R (2000) Objective evaluation of improvement in optic neuropathy following radiation therapy for thyroid eye disease. Int J Radiat Oncol Biol Phys 47(1):191\u2013194","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2036_CR110","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/01676838909012334","volume":"8","author":"A Threlkeld","year":"1989","unstructured":"Threlkeld A, Miller NR, Wharam M (1989) The efficacy of supervoltage radiation therapy in the treatment of dysthyroid optic neuropathy. Orbit 8(4):253\u2013264. https:\/\/doi.org\/10.3109\/01676838909012334","journal-title":"Orbit"},{"issue":"7","key":"2036_CR111","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/archopht.1978.03910060033007","volume":"96","author":"JD Trobe","year":"1978","unstructured":"Trobe JD, Glaser JS, Laflamme P (1978) Dysthyroid optic neuropathy. Clinical profile and rationale for management. Arch Ophthalmol 96(7):1199\u20131209","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"2036_CR112","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0002-9394(14)76027-1","volume":"99","author":"T Hurbli","year":"1985","unstructured":"Hurbli T, Char DH, Harris J, Weaver K, Greenspan F, Sheline G (1985) Radiation therapy for thyroid eye diseases. Am J Ophthalmol 99(6):633\u2013637","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2036_CR113","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00417-016-3280-7","volume":"254","author":"JW Kim","year":"2016","unstructured":"Kim JW, Han SH, Son BJ, Rim TH, Keum KC, Yoon JS (2016) Efficacy of combined orbital radiation and systemic steroids in the management of Graves\u2019 orbitopathy. Graefe\u2019s Arch Clin Exp Ophthalmol. 254(5):991\u2013998","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol."},{"issue":"6","key":"2036_CR114","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.ajo.2014.02.044","volume":"157","author":"PN Shams","year":"2014","unstructured":"Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ (2014) Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 157(6):1299\u20131305","journal-title":"Am J Ophthalmol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02036-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02036-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02036-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T05:10:23Z","timestamp":1701925823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02036-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,18]]},"references-count":114,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2036"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02036-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,18]]},"assertion":[{"value":"24 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}